Zodasiran targets ANGPLT3, an emerging therapeutic target to treat HoFH and other dyslipidemias – YOSEMITE Phase 3 study further enhances Arrowhead’s late-stage pipeline o ...

NEW YORK, NY, USA I July 8, 2025 I Myrtelle Inc. (“Myrtelle” or the “Company”), a pioneering clinical-stage gene therapy company dedicated to revolutionizing treatment for neurodegenerative diseases, ...

Nature–evolved chemistry, human insight, and AI converge to advance a new generation of brain and mental health medicines ...

MIAMI, FL, USA and JERUSALEM, Israel I July 08, 2025 I OPKO Health, Inc. (NASDAQ: OPK) (“OPKO”) and Entera Bio Ltd. (NASDAQ: ENTX) (“Entera”) today announced ...

SAFEbody® is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union.

LONDON, UK I July 09, 2025 I Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announces ...

SAN DIEGO, CA, USA I July 08, 2025 I Eluciderm, Inc., a clinical-stage pharmaceutical company developing small molecule therapeutics designed to promote ...

The agreement enables process and analytical development activities required to advance Nimvec™ AM510 for Type 1 Diabetes toward cGMP manufacturing and first-in-human clinical trials Strengthening the ...

Enabling efficient nose-to-brain drug delivery, MetP® offers an alternative to injection-based administration - targeting a $150 billion obesity and ...

HYOGO, Japan I July 8, 2025 I JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”) today announced that it has entered into a license agreement with Alexion, ...

I Taiho Pharmaceutical Co., Ltd. announced that the results of a phase III, randomized, placebo-controlled, double-blind and open-label, ...

JERSEY CITY, NJ, USA I July 7, 2025 I Celltrion USA today announced that STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo), biosimilars referencing ...